Part,  Chapter, Paragraph

1   II,     9        | balance risks and benefits. Pharmacovigilance or postmarketing surveillance
2   II,     9.  1.  2| balance risks and benefits. Pharmacovigilance or postmarketing surveillance
3   II,     9.  1.  2|    initiation of the EnCePP pharmacovigilance network by the European
4   IV,    12. 10    |    continually a program of Pharmacovigilance~ ~o Greece participates